DexCom (NASDAQ:DXCM) Stock Price Target Raised at Barclays

Key Points

• Barclays raised DexCom’s price target to $120 from $115 and maintained an “overweight” rating, implying approximately 41.9% upside from the previous close.
• DexCom shares rose 5.8% to $84.54, while the company’s latest quarterly results exceeded expectations: EPS was $0.73 versus a $0.68 consensus estimate, and revenue reached $1.34 billion, up 11.1% year over year.
• Analyst sentiment remains broadly positive, with MarketBeat reporting an average “Buy” rating and a $92.78 average price target; however, insiders sold 24,822 shares worth about $2.1 million over the past 90 days.

DexCom (NASDAQ:DXCM - Get Free Report) had its price target lifted by equities researchers at Barclays from $115.00 to $120.00 in a research report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the medical device company's stock. Barclays's price objective suggests a potential upside of 41.94% from the stock's previous close.

DXCM has been the topic of a number of other research reports. BTIG Research lifted their target price on DexCom from $90.00 to $96.00 and gave the stock a "buy" rating in a research report on Monday, October 12th. Mizuho set a $100.00 price target on DexCom in a research note on Tuesday, October 13th. Wells Fargo & Company raised their price target on DexCom from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Robert W. Baird set a $105.00 price objective on DexCom in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, DexCom has an average rating of "Buy" and an average target price of $92.78.

DexCom Stock Up 5.8%

DXCM stock traded up $4.61 during trading on Friday, hitting $84.54. 2,253,831 shares of the company's stock were exchanged, compared to its average volume of 5,000,788. The business has a 50-day moving average price of $85.98 and a two-hundred day moving average price of $74.60. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $31.90 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 1.32 and a beta of 1.48. DexCom has a 52-week low of $54.11 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.05. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the firm posted $0.61 EPS. The company's revenue was up 11.1% on a year-over-year basis. As a group, equities research analysts expect that DexCom will post 2.64 EPS for the current year.

Insiders Place Their Bets

In related news, Director Mark G. Foletta sold 2,000 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director owned 48,852 shares in the company, valued at $4,168,052.64. The trade was a 3.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director directly owned 29,293 shares of the company's stock, valued at approximately $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 24,822 shares of company stock valued at $2,090,833. 0.28% of the stock is owned by insiders.

Hedge Funds Weigh In On DexCom

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mather Group LLC. raised its holdings in DexCom by 27.7% during the third quarter. Mather Group LLC. now owns 563 shares of the medical device company's stock worth $49,000 after purchasing an additional 122 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its position in DexCom by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company's stock worth $475,000 after purchasing an additional 150 shares during the period. Elevation Wealth Partners LLC increased its position in DexCom by 61.0% during the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock worth $35,000 after purchasing an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in shares of DexCom by 15.4% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company's stock worth $77,000 after buying an additional 153 shares in the last quarter. Finally, Simplicity Wealth LLC raised its stake in shares of DexCom by 5.4% during the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company's stock worth $273,000 after buying an additional 162 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Strong third-quarter results: DexCom reported adjusted earnings of $0.73 per share, exceeding consensus estimates of approximately $0.66–$0.68, while revenue of $1.34 billion topped expectations by about $10 million. Revenue increased roughly 11% year over year, and operating profit rose sharply, highlighting continued margin improvement. DexCom Third-Quarter Earnings Results
• Positive Sentiment: Higher outlook: Management raised its 2026 sales guidance, reinforcing investor confidence that demand for DexCom’s continuous glucose monitoring products remains resilient. DexCom Raises Sales Guidance
• Positive Sentiment: $1 billion buyback: DexCom authorized an equity repurchase program worth up to $1.0 billion. The plan may support earnings per share and signals that management views the company’s shares as an attractive use of capital. DexCom Announces $1 Billion Buyback
• Positive Sentiment: Product expansion: DexCom plans to launch its G7 15-day continuous glucose monitoring system in Canada in November, expanding the availability of its newest platform. DexCom G7 15-Day Canada Launch
• Negative Sentiment: Insider selling: Executive Vice President Sadie Stern sold 2,565 shares for approximately $202,000 under a pre-arranged Rule 10b5-1 plan. The scheduled nature of the transaction reduces its significance, but continued insider sales may temper sentiment. DexCom Insider Sale

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.